The National Cancer Institute of Milan (INT), established in 1928, stands as a centre of excellence for pre-clinical, translational, and clinical research activities, and clinical care.
INT is a comprehensive national tertiary cancer centre, as it has 464 inpatient beds and provides more than 400,000 outpatient visits a year. The Institute carries out a public service characterised by a high level of diagnostic therapeutic and research activities. Indeed, it has programs and projects in every field and phase of research, preclinical, epidemiological, public health and clinical, being also the Italian coordinator of numerous national and international clinical trials also with early phase studies. The inseparability, reciprocity, and the functional continuum between clinic and research combined with the access to continuing care facilities qualify INT as a Comprehensive Cancer Centre, according to the criteria of the Organisation of European Cancer Institutes (OECI).
The centre is divided into different departments. The clinical department includes Medical Oncology and Haematology, Surgery, Radiology and Radiotherapy. The Palliative Care Programme, which is part of the Medical Oncology and Haematology department, includes a hospice unit, outpatient clinic, inpatient consult service, and home care. INT is also committed to professional training and education with formalised activities, hosting numerous university chairs, medical and nursing training programs.
Role within MyPath: The INT team in MyPath is committed to developing the content of the patient-centred care pathways within WP1 and WP2. It will also participate in the MyPath implementation study, which will mainly involve the lung cancer outpatient clinic.